Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep251 | Pituitary and Neuroendocrinology | ECE2024

Diagnostic challenges in cyclic cushing’s syndrome: a rare case due to ectopic acth secretion by lung carcinoid

Colle Roberto , Pigni Stella , Jaafar Simona , Cristofolini Giacomo , Francesca Birtolo Maria , Lavezzi Elisabetta , Bottoni Edoardo , Uccella Silvia , Mazziotti Gherardo , Lania Andrea

Introduction: Cyclic Cushing’s syndrome (cCS) is a rare condition characterized by periods of excessive cortisol secretion (peaks), alternating with phases of eucortisolism (through). In most cases, cCS is caused by an ACTH-secreting pituitary tumor, while only few cases of cyclic ectopic ACTH secretion (cEAS) have been described.Case presentation: In February 2023, a 58-year-old woman was referred to our Endocrine Unit due to a 10-year history of r...

ea0099p450 | Calcium and Bone | ECE2024

A pharmacoeconomic analysis from Italian guidelines for the management of sporadic primary hyperparathyroidism

Attanasio Roberto Samperi Irene , Scoppola Alessandro , Paoletta Agostino , Novizio Roberto , Vescini Fabio , Borretta Giorgio , Chiodini Iacopo , Papini Enrico , Persichetti Agnese , Basile Michele , Boniardi Marco , Carotti Marina , Castellano Elena , Cipriani Cristiana , Eller-Vainicher Cristina , Giannini Sandro , Iacobone Maurizio , Salcuni Antonio/////Stefano , Saponaro Federica , Spiezia Stefano , Versari Annibale , Zavatta Guido , Mitrova Zuzana , Giovannazzi Alexia , Saulle Rosella , Vecchi Simona , Antonini Debora , Calo Giorgio , Cetani Filomena , Cianferotti Luisella , Corbetta Sabrina , De Rimini Maria Luisa , Falchetti Alberto , Iannetti Giovanni , Laureti Stefano , Lombardi Celestino/////Pio , Madeo Bruno , Marcocci Claudio , Mazzaferro Sandro , Miele Vittorio , Minisola Salvatore , Palermo Andrea , Pepe Jessica , Tonzar Laura , Scillitani Alfredo , Grimaldi Franco , Cozzi Renato , Attanasio Roberto

Background: Primary hyperparathyroidism (PHPT) is the third most common endocrine disease and the most frequent cause of hypercalcemia in outpatients with an estimated incidence of 20/100 000/year and prevalence in the general population of 0.1%–0.4%. Parathyroidectomy (PTX) is the only treatment that can achieve PHPT cure but a few medications can be used to control calcium levels, bone and kidney impairment.Aims: 1) To assess costs associated with...

ea0081p305 | Calcium and Bone | ECE2022

Reliability of who fracture risk assessment tool (frax) and bone mineral density in predicting fractures in cancer patients under hormone deprivation therapies: a real-world clinical study

Vena Walter , Piccini Sara , Pedersini Rebecca , Carrone Flaminia , Cosentini Deborah , Zucali Paolo , Torrisi Rosalba , Brunetti Alessandro , Pigni Stella , Maroldi Roberto , Balzarini Luca , Lania Andrea Gerardo , Berruti Alfredo , Berruti Gherardo

Background: Skeletal fragility is an important clinical issue in women with early-stage breast cancer and men with non-metastatic prostate cancer under hormonal hormone deprivation therapies (HDTs). Vertebral fractures (VFs) have been reported in a remarkable number of subjects exposed to HDT especially when the diagnosis of fractures is performed by a radiological and morphometric approach. Notably, prediction of fractures in this clinical setting is a challenge and determina...

ea0081p333 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

REAL Life study of SEMaglutide in Patients with Type 2 diabetes in SPain (REALSEM-SP): Retrospective clinical study on the efficacy, adherence, and safety with Semaglutide

Cardenas Salas Jersy Jair , Poyatos Roberto Miguel Sierra , Luiza Luca Bogdana , Sanchez Lechuga Begona , Modrono Mostoles Naiara , Montoya Alvarez Teresae , GoMez Montes Maria De La Paz , Sanchez-Lopez Raquel , Casado Carlos , Vazquez Martinez Clotilde

Introduction: Real-world data on glucose and weight control effectiveness in patients with Type 2 diabetes mellitus (T2DM) on treatment with semaglutide is scarce. We aim to assess it in a cohort of patients from a real-world setting in Spain.Materials and methods: We identified 830 patients with T2DM that were prescribed Semaglutide once-weekly since May 2019 to December 2020, in 4 hospitals in Madrid-Spain. At 6±3 months, 435 GPL1-naïve and 3...

ea0081ep695 | Pituitary and Neuroendocrinology | ECE2022

Epidemiological description of 20 years of experience in the management of insulinomas in a third level hospital

Maricel Rivas Montenegro Alejandra , Ramos Roberto Jose An ez , Belinchon Sergio Santos , Gonzalez Fernandez Laura , Moreno Diego Mun oz , Fernandez Fernandez Elisa , Salas Marcel Sambo , Hualpa Juan Carlos Percovich , Gonzalez Albarran Olga , Garcia Centeno Rogelio

Introduction: Insulinoma, despite its low incidence of 0.4%, it is the most common functioning pancreatic neuroendocrine tumor. Most are benign, solitary and sporadic. Around 10% can be malignant and 5-10% are part of MEN-1. On certain occasions, the differential diagnosis is difficult when there is a history of Diabetes Mellitus (DM). Our objective was to describe clinical-epidemiological data and its diagnostic-therapeutic management.Materials and Meth...

ea0090p336 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Oral Semaglutide Improves Metabolic Outcomes in Type 2 Diabetes: A Spain-based Study

Casado Carlos , Jair Cardenas Salas Jersy , Miguel Sierra Poyatos Roberto , Montoya Alvarez Teresa , Meneses Gonzalez Diego , Gabriel Ruiz Sanchez Jorge , Luiza Luca Bogdana , Sanchez Lechuga Begona , de los Angeles Velez Romero Maria , Vazquez Martinez Clotilde

Objectives: To evaluate the changes in HbA1c, basal glucose, weight, and lipid profile in patients with type 2 diabetes after starting oral semaglutide.Methods: This study was conducted in Madrid, Fundación Jiménez Díaz, Infanta Elena and General de Villalba hospitals. A total of 75 patients with type 2 diabetes were included. The mean age was 62.0±10.5 years and 60% were men. The mean duration of diabetes was 7.3±6.6 years, and 66.7...

ea0090ep686 | Pituitary and Neuroendocrinology | ECE2023

Inferior petrosal sinus sampling and stimulation with CRH: 18 years of experience in a tertiary hospital

Montenegro Alejandra Maricel Rivas , Anez Roberto , Gonzalez Fernandez Laura , Munoz Diego , Garcia Piorno Alberto , Losada Gata Isabel , Gomez-Gordo Hernanz Monica , Collado Gonzalez Gloria , Carlos Percovich Juan , Gonzalez Albarran Olga , Garcia Centeno Rogelio

Background: Inferior petrosal sinus sampling (IPSS) is indicated in the diagnosis of adrenocor-ticotropic hormone (ACTH)-dependent Cushing’s syndrome (CS), especially when the results of the initial diagnostic tests are discordant.Objective: To describe the patients who underwent this invasive functional test in a tertiary hospital.Methods: This was an observational study of a retrospective cohort of patients with ACTH- depend...

ea0063gp20 | Calcium and Bone 1 | ECE2019

Clinical, biochemical and radiological profile of normocalcaemic hyperparathyroidism: a multicentric cross-sectional evaluation

Naciu Anda Mihaela , Tabacco Gaia , Falcone Stefania , Santonati Assunta , Maggi Daria , D'Onofrio Luca , Briganti Silvia Irina , Castellitto Domenico , Casini Alessandro , Pedone Claudio , Fabbri Andrea , Napoli Nicola , Pozzilli Paolo , Manfrini Silvia , Cesareo Roberto , Palermo Andrea

Background: The normocalcaemic hyperparathyroidism (NHPT) has been defined as a condition with persistently normal total and ionized calcium levels in the presence of high levels of PTH. The clinical aspects of NHPT have been evaluated in different cohorts but the interpretation of these findings is confounded by differing methods used to rule out secondary hyperparathyroidism and by the small number of NHPT subjects enrolled. Up to now, there is no information available that ...

ea0049gp178 | Pituitary | ECE2017

Sleep patterns in patients with non-functional GHRH receptor

Oliveira Francielle T , Salvatori Roberto , Marcondes Jose , Macena Larissa B , Oliveira-Santos Alecia A , Faro Augusto C N , Campos Viviane C , Oliveira Carla R P , Costa Ursula M M , Aguiar-Oliveira Manuel H

Hypothalamic GH releasing hormone (GHRH) has hypnotic actions by increasing slow wave sleep (SWS) (non-rapid eye movement sleep, non-REM), which account for about 75% of sleep. Conversely, GH may stimulate the rapid eye movement sleep (REM). Patients with GH deficiency (GHD) often exhibit sleep problems leading to daytime fatigue and reduced quality of life (QoL). We have described a cohort of patients with isolated GHD (IGHD) due to GHRH resistance caused by a homozygous null...

ea0049ep949 | Pituitary - Clinical | ECE2017

Ocular findings in adult subjects with congenital, lifetime, isolated, untreated growth hormone deficiency

Faro Augusto C N , Pereira-Gurgel Virginia M , Salvatori Roberto , Campos Viviane C , Melo Gustavo B , Oliveira Francielle T , Oliveira-Santos Alecia A , Oliveira Carla R P , Pereira Francisco A , Hellstrom Ann , Oliveira-Neto Luis A , Aguiar-Oliveira Manuel H

Ocular function is fundamental for environmental adaptation and survival capacity. Growth factors are thought to be necessary to reach a mature eyeball and consequent adequate vision. However, the consequences of the deficiency of circulating growth hormone (GH) and its effector insulin-like growth factor I (IGF-I) on the physical aspects of the human eye are still debated. A model of untreated isolated GH deficiency (IGHD) may clarify this issue. The aim of this study was to ...